Literature DB >> 11478419

Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients.

M M Garcia-Barceló1, L C Lam, G S Ungvari, V K Lam, W K Tang.   

Abstract

Epidemiological studies have shown a lower prevalence of tardive dyskinesia (TD) among Chinese psychiatric patients compared to Caucasian and Black patient populations. It has been hypothesized that pharmacogenetic factors may underlie this cross-cultural difference. Due to the important implications of the dopamine D3 receptor gene (DRD3) in motor control, we investigated the frequency of polymorphic serine (ser) to glycine (gly) substitution of the gene DRD3 in Chinese schizophrenic patients. The sample size consisted of 65 patients with TD and 66 without TD. Patients were assessed for the severity of TD, the presence of akathisia and parkinsonian symptoms and were subsequently genotyped. We found no evidence that the dopamine D3 receptor gene is likely to confer susceptibility to the development of tardive dyskinesia in Chinese patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478419     DOI: 10.1007/s007020170044

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  9 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 3.  Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation.

Authors:  Bernard Lerer; Ronnen H Segman
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 4.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 5.  Pharmacogenetics as a tool in the therapy of schizophrenia.

Authors:  Bob Wilffert; Rianne Zaal; Jacobus R B J Brouwers
Journal:  Pharm World Sci       Date:  2005-02

6.  Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients.

Authors:  Ying-Jay Liou; Ding-Lieh Liao; Jen-Yeu Chen; Ying-Chieh Wang; Chao-Cheng Lin; Ya-Mei Bai; Shun-Chieh Yu; Ming-Wei Lin; I-Ching Lai
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 7.  Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Authors:  Evangelia Eirini Tsermpini; Sara Redenšek; Vita Dolžan
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

8.  Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians.

Authors:  Adriana Foster; Zixuan Wang; Manzoor Usman; Edna Stirewalt; Peter Buckley
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

Review 9.  Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.

Authors:  Mujeeb U Shad
Journal:  Behav Sci (Basel)       Date:  2021-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.